...
首页> 外文期刊>Cell death & disease. >Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53
【24h】

Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53

机译:肿瘤抑制因子p53对癌症干细胞标志物CD133的转录抑制

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Novel therapeutic strategies are needed to overcome cancer recurrence, metastasis, and resistance to chemo- and radiotherapy. Cancer stem cells (CSCs) are major contributors to the malignant transformation of cells due to their capacity for self-renewal. Although various CSC markers have been identified in several types of tumors, they are primarily used as cancer-prediction markers and for the isolation of CSC populations. CD133, one of the best-characterized CSC markers in distinct solid tumor types, was shown to be correlated with CSC tumor-initiating capacity; however, the regulation of CD133 expression and its function in cancer are poorly understood. Here, we show that CD133 expression is negatively regulated by direct binding of the p53 tumor suppressor protein to a noncanonical p53-binding sequence in the CD133 promoter. Binding of p53 recruits Histone Deacetylase 1 (HDAC1) to the CD133 promoter and subsequently suppresses CD133 expression by reducing histone H3 acetylation. Furthermore, CD133 depletion suppresses tumor cell proliferation, colony formation, and the expression of core stemness transcription factors including NANOG, octamer-binding transcription factor 4 (OCT4), SOX2, and c-MYC. Critically, the anti-proliferative effects of p53 are antagonized by rescue of CD133 expression in a p53 overexpressing cell line, indicating that the tumor suppressive activity of p53 might be mediated by CD133 suppression. Taken together, our results suggest that p53-mediated transcriptional regulation of CD133 is a key underlying mechanism for controlling the growth and tumor-initiating capacity of CSCs and provide a novel perspective on targeting CSCs for cancer therapy.
机译:需要新的治疗策略来克服癌症的复发,转移以及对化学疗法和放射疗法的抵抗力。癌症干细胞(CSC)由于其自我更新的能力而成为细胞恶性转化的主要因素。尽管已在几种类型的肿瘤中鉴定出各种CSC标记,但它们主要用作癌症预测标记和CSC群体的分离。 CD133是不同实体瘤类型中最典型的CSC标记之一,已显示与CSC肿瘤起始能力相关。然而,人们对CD133表达的调节及其在癌症中的功能了解甚少。在这里,我们显示CD133表达受到p53抑癌蛋白与CD133启动子中非典型p53结合序列直接结合的负调控。 p53的结合募集组蛋白脱乙酰基酶1(HDAC1)与CD133启动子,并随后通过减少组蛋白H3乙酰化来抑制CD133表达。此外,CD133耗竭抑制肿瘤细胞增殖,集落形成和核心干转录因子(包括NANOG,八聚体结合转录因子4(OCT4),SOX2和c-MYC)的表达。至关重要的是,p53的抗增殖作用被p53过表达细胞系中CD133表达的抢救所拮抗,表明p53的抑癌活性可能是CD133抑制所介导的。综上所述,我们的结果表明,p53介导的CD133转录调控是控制CSCs生长和肿瘤启动能力的关键基础机制,并为靶向CSCs用于癌症治疗提供了新的视角。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号